Venture Capital

June 24, 2018

Strategies That Chinese Small and Medium-Sized Enterprises Use to Attract Venture Capital

Abstract Small and medium-sized enterprises (SMEs) contribute to China’s economic growth and help maintain social stability. However, SME business leaders have cited access to finance as an obstacle of SMEs’ survival and success. The purpose of this multiple case study was to identify main strategies SME entrepreneurs and business leaders used to attract venture capital… Continue reading

Private Equity, Venture Capital

April 16, 2014

Venture Capital in Life Sciences (III): Monoclonal Antibodies in the Treatment of Ankylosing Spondylitis

The application of monoclonal antibody drugs is a relatively new innovation. Approximately 54% of monoclonal antibody drugs available are applied in various types of cancer, although clinical trials are also studying monoclonal drugs in autoimmune diseases, and sex organ transplants. When a monoclonal antibody attaches to a cancer cell, it can make the cancer cell… Continue reading

Healthcare Fund, Life Sciences, Venture Capital

April 7, 2014

Venture Capital in Life Sciences (II): Pharmacogenomics and Personalized Medicine

Pharmacogenomics focuses on understanding the response rates and side effects of a treatment at the individual level. It analyzes the influence of genetic variation on drug response in patients by correlating gene expression or single-nucleotide polymorphisms with the efficacy or toxicity of a drug, hence improves clinical outcomes. The field of pharmacogenomics has applied in… Continue reading

Healthcare Fund, Life Sciences, Venture Capital

March 30, 2014

Biomedicine: Healthcare Venture Capital’s Investment of 2014

As a venture capitalist, I believe the hottest investment of 2014 is in the healthcare sector. The beauty of healthcare investing lies in the fact that the demand for the sector is relatively inelastic; if a patient has a heart attack, or a new antitumor drug is discovered and developed, the demand will be completely… Continue reading

Healthcare Fund, Life Sciences, Venture Capital

February 24, 2014

Venture Capital in Life Sciences (I): Personalized Medicine for Cancer Therapies

Over the past decade, the genomics revolution has led to the emergence of numerous groundbreaking personalized medicine as well as multiple diagnostic and therapeutic targets. Take the area of cancer therapies for instance, due to great inter-personal difference and mechanism of drug sensitivity in patients, cancer is one of the diseases that have lowest productivity… Continue reading

Alternative Investments, Healthcare Fund, Life Sciences, Venture Capital

February 17, 2014

Healthcare Investing: In Innovators We Trust, Up to the Future We Light

When people talk about “healthcare,” they probably refer to pharmaceuticals and health insurers, but the sector also covers life sciences and biotechnology, medical equipment manufacturers and services, hospitals, distributors, etc. My firm conducted a due diligence trip to China and visited many scientists of these fields in Beijing, Shanghai, and some southern cities in January… Continue reading

Alternative Investments, Healthcare Fund, Private Equity, Venture Capital

February 10, 2014

Crowdfunding: A Powerful Model of Fundraising 众筹融资

Crowdfunding is an internet-based fundraising model, where individuals network and pool their money to support a certain project or venture. A crowdfunding activity is composed of a project creator, crowd or the public who will support the project or venture, and a crowdfunding platform. The “crowd” act as agents, selecting and promoting the projects in… Continue reading

Private Equity, Venture Capital

October 20, 2013

Impact Investing – The Next Generation of Venture Capital

In the 1990s, Jed Emerson advocated the concept of Blended Value for funds, firms, social ventures, and foundations to invest with social and environmental impact, rather than to maximize financial performance. Simultaneously, approaches such as pollution prevention, corporate social responsibility (CSR), and triple bottom line or the “three pillars” (people, planet, and profit) began to… Continue reading

Alternative Investments, Private Equity, Socially Impact Investing, Venture Capital

October 18, 2013

Venture Capital and Buyout

The Yale Endowment’s investment success has been largely driven by the categories that are designed for sophisticated investors, such as PE. Ten years ending June 30, 2013, the endowment fund’s U.S. equities returned 10.8%, while PE portfolio returned 14.4% per annum. Yale’s PE investments include venture capital (VC) and leveraged buyouts (LBOs) Venture Capital After… Continue reading

Alternative Investments, Buyout, Private Equity, Venture Capital

Archive

Newsletter